Aliases & Classifications for Leiomyoma

MalaCards integrated aliases for Leiomyoma:

Name: Leiomyoma 12 75 55 44 15
Leiomyomatous Neoplasm 12
Leiomyomatous Tumor 12
Uterine Fibroids 72
Fibroid Tumor 72
Leiomyomas 15

Classifications:



External Ids:

Disease Ontology 12 DOID:127
MeSH 44 D007889
NCIt 50 C3157
UMLS 72 C0023267 C0042133

Summaries for Leiomyoma

Disease Ontology : 12 A cell type benign neoplasm that is a benign tumor of smooth muscle cells.

MalaCards based summary : Leiomyoma, also known as leiomyomatous neoplasm, is related to leiomyoma, uterine and bizarre leiomyoma, and has symptoms including pelvic pain An important gene associated with Leiomyoma is FH (Fumarate Hydratase), and among its related pathways/superpathways are Pathways in cancer and AGE-RAGE signaling pathway in diabetic complications. The drugs Dienogest and Nandrolone phenpropionate have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and breast, and related phenotypes are no effect and Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435)

Wikipedia : 75 A leiomyoma, also known as fibroids, is a benign smooth muscle tumor that very rarely becomes cancer... more...

Related Diseases for Leiomyoma

Diseases related to Leiomyoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 782)
# Related Disease Score Top Affiliating Genes
1 leiomyoma, uterine 35.0 RAD51B PGR HMGA2 FH ESR1
2 bizarre leiomyoma 34.9 PGR MED12 ACTC1
3 lung leiomyoma 34.7 PGR ESR1
4 vulvar leiomyoma 34.6 PGR ESR1
5 orbital leiomyoma 34.3 S100A1 GNRH1
6 benign metastasizing leiomyoma 34.1 PGR DES CYP19A1 ACTC1
7 gastrointestinal stromal tumor 32.7 S100A1 DES CD34 ACTC1
8 leiomyomatosis 32.1 PGR MED12 GNRH1 FH ESR1 COL4A6
9 leiomyosarcoma 31.8 S100A1 PGR MED12 FH DES CAPN6
10 intravenous leiomyomatosis 31.7 MME ESR1 DES
11 myoma 31.6 PGR MED12 HMGA2 GNRH1 ESR1 CYP19A1
12 pleomorphic lipoma 31.5 PGR HMGA2
13 mesenchymoma 31.4 HMGA2 DES
14 lymphangioleiomyomatosis 31.3 PGR ESR1 DES
15 prostatic hypertrophy 31.2 PGR ESR1 CYP19A1
16 endometriosis 31.1 PGR GNRH1 ESR2 ESR1 CYP19A1
17 angiomyolipoma 31.0 PGR ESR1 DES ACTC1
18 adenomyosis 30.9 PGR MME GNRH1 ESR1 CYP19A1
19 smooth muscle tumor 30.9 PGR MME HMGA2 ESR1 DES ACTC1
20 liposarcoma 30.9 HMGA2 DES CD34
21 uterine sarcoma 30.9 MME ESR1 DES CYP19A1
22 gynecomastia 30.8 PGR ESR1 CYP19A1
23 uterine anomalies 30.8 PGR ESR1 CYP19A1
24 epithelioid leiomyosarcoma 30.7 DES ACTC1
25 endometrial adenocarcinoma 30.7 PGR ESR2 ESR1
26 meningioma, familial 30.7 PGR ESR1 CD34
27 bartholin's gland benign neoplasm 30.6 PGR ESR1
28 diffuse peritoneal leiomyomatosis 30.6 PGR MED12 ESR1 CD34
29 myxoid leiomyosarcoma 30.6 PGR MME ACTC1
30 cutaneous leiomyosarcoma 30.5 FH DES ACTC1
31 endometriosis of ovary 30.5 PGR ESR2 ESR1 CYP19A1
32 estrogen excess 30.4 PGR ESR2 ESR1 CYP19A1
33 breast disease 30.3 PGR ESR2 ESR1 CYP19A1
34 reticulum cell sarcoma 30.3 S100A1 DES ACTC1
35 glomangiomyoma 30.3 ESR1 CD34 ACTC1
36 carcinosarcoma 30.2 PGR MME DES ACTC1
37 endometrial stromal sarcoma 30.2 PGR MME ESR1 DES CYP19A1 ACTC1
38 dermatofibrosarcoma protuberans 30.1 DES CD34 ACTC1
39 endometrial cancer 30.1 PGR MME GNRH1 ESR2 ESR1 CYP19A1
40 endometrial stromal nodule 30.0 PGR MME CYP19A1
41 benign breast phyllodes tumor 30.0 PGR MME
42 breast myofibroblastoma 29.8 MME ESR1 CD34
43 perivascular epithelioid cell tumor 29.8 PGR MME DES ACTC1
44 adenofibroma 29.8 MME ACTC1
45 breast fibroadenoma 29.7 PGR MME MED12 HMGA2 ESR1 CYP19A1
46 cellular leiomyoma 12.5
47 deep leiomyoma 12.5
48 hereditary leiomyomatosis and renal cell cancer 12.4
49 uterine corpus bizarre leiomyoma 12.4
50 leiomyoma cutis 12.4

Graphical network of the top 20 diseases related to Leiomyoma:



Diseases related to Leiomyoma

Symptoms & Phenotypes for Leiomyoma

UMLS symptoms related to Leiomyoma:


pelvic pain

GenomeRNAi Phenotypes related to Leiomyoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ACTC1 CAPN6 CD34 COL4A5 COL4A6 CYP19A1
2 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 9.26 ESR1 ESR2 FH RAD51B

MGI Mouse Phenotypes related to Leiomyoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.14 ACTC1 CD34 CYP19A1 DES ESR1 ESR2
2 cardiovascular system MP:0005385 10.13 ACTC1 COL4A5 CYP19A1 DES ESR1 ESR2
3 homeostasis/metabolism MP:0005376 10.13 ACTC1 CD34 COL4A5 CYP19A1 DES ESR1
4 immune system MP:0005387 9.96 CD34 COL4A5 CYP19A1 ESR1 ESR2 GNRH1
5 digestive/alimentary MP:0005381 9.91 CAPN6 CYP19A1 ESR1 ESR2 GNRH1 IL17B
6 integument MP:0010771 9.76 CD34 CYP19A1 DPT ESR1 ESR2 GNRH1
7 muscle MP:0005369 9.56 ACTC1 CAPN6 CYP19A1 DES ESR1 ESR2
8 normal MP:0002873 9.32 ACTC1 COL4A6 CYP19A1 ESR1 ESR2 GNRH1

Drugs & Therapeutics for Leiomyoma

Drugs for Leiomyoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 242)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dienogest Approved Phase 4 65928-58-7
2
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 4 62-90-8 229455
3
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
4
Ferrous fumarate Approved Phase 4 141-01-5
5
Methylcobalamin Approved, Experimental, Investigational Phase 4 13422-55-4
6
leucovorin Approved Phase 4 58-05-9 143 6006
7
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
10
Zinc oxide Approved Phase 4 1314-13-2
11
Calcium carbonate Approved, Investigational Phase 4 471-34-1
12
Zinc Approved, Investigational Phase 4 7440-66-6 32051
13
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Dinoprostone Approved Phase 4 363-24-6 5280360
16
Goserelin Approved Phase 4 65807-02-5, 1233494-97-7 47725 5311128
17
Cetrorelix Approved, Investigational Phase 4 120287-85-6 25074887 16129715
18
Acetaminophen Approved Phase 4 103-90-2 1983
19
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Misoprostol Approved Phase 4 59122-46-2 5282381
22
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
23
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
24
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
25
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
26
Levonorgestrel Approved, Investigational Phase 4 797-63-7, 17489-40-6 13109
27
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
28
Polyestradiol phosphate Approved Phase 4 28014-46-2
29
Tranexamic Acid Approved Phase 4 1197-18-8 5526
30
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
31
Mifepristone Approved, Investigational Phase 4 84371-65-3 55245
32
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
33
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
34
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
35
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
36
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
37
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
38
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
39
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
40
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
41
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 59-43-8, 70-16-6 1130
42
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
43
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 54670067 5785
44
Beta carotene Approved, Nutraceutical Phase 4 7235-40-7
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
46
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
47
Nandrolone Experimental, Investigational Phase 4 434-22-0 9904
48
Cobalamin Experimental Phase 4 13408-78-1 6857388
49
Fibrinolysin Investigational Phase 4 9004-09-5
50 Deslorelin Investigational, Vet_approved Phase 4 57773-65-6

Interventional clinical trials:

(show top 50) (show all 371)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of High Intensity Focused Ultrasound Ablation Compared With Myomectomy in Uterine Fibroids:A Randomized Controlled Study Unknown status NCT01239641 Phase 4
2 Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas Unknown status NCT02361905 Phase 4 ulipristal acetate;Leuprolide acetate
3 Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women Unknown status NCT02440750 Phase 4 Dienogest;Ulipristal acetate
4 Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin Unknown status NCT01738724 Phase 4 Dienogest;Goserelin;Desogestrel
5 The Effect of UPA on Women Ovarian Reserve Unknown status NCT02361892 Phase 4 ulipristal acetate
6 IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure Unknown status NCT02601196 Phase 4 Ulipristal acetate
7 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Unknown status NCT02361879 Phase 4 ulipristal acetate;Leuprolide acetate
8 Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2 Unknown status NCT02357563 Phase 4 ulipristal acetate;Leuprolide acetate
9 The FIRSTT Study: Comparing Focused Ultrasound and Uterine Artery Embolization for Uterine Fibroids Completed NCT00995878 Phase 4
10 Pilot of Letrozole for Uterine Myomas Completed NCT02470741 Phase 4 Letrozole
11 A Prospective, Randomized, Single-Center Study Comparing Contour SE™ Microspheres to Embosphere® Microspheres for Treating Symptomatic Uterine Fibroids With Uterine Fibroid Embolization (UFE) Completed NCT00628901 Phase 4
12 Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy Completed NCT02620345 Phase 4 Dydrogesterone M ( case 1 );Dydrogesterone M ( case 2 )
13 Efficacy and Safety of Prevadh™ in the Prevention of Adhesions in Gynaecological Surgery: a Multicenter, Randomized, French Study Completed NCT01388907 Phase 4
14 Novel Magnetic Resonance Imaging Strategies as a Non-invasive Biomarker of Vascular and Extracellular Matrix Morphology in Women With Uterine Fibroids. Completed NCT00746031 Phase 4 GnRH analogue (Zoladex);GnRH antagonist-Cetrorelix
15 A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
16 Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study Completed NCT02293447 Phase 4 Lidocaine per-embolization;Lidocaine post-embolization
17 Understanding Experimentally Induced Hot Flushes and Their Impact on Sleep and Mood Completed NCT00455689 Phase 4 Leuprolide acetate
18 Single Versus Double Dose Intra-vaginal Prostaglandin E2 "Misoprostol" Prior Abdominal Myomectomy: A Randomized Controlled Study Completed NCT02154932 Phase 4 2 doses 400 microgram misoprostol;single dose misoprostol
19 Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy Completed NCT03308643 Phase 4 Oxytocin
20 Impact of Experimentally Induced Hot Flashes on Sleep and Mood Disturbance Completed NCT01116401 Phase 4 leuprolide
21 GYNAECARE MORCELLEX Tissue Morcellator vs. ROTOCUT GI Tissue Morcellator: a Randomized Controlled Study Completed NCT00743080 Phase 4
22 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure, a Randomized Trial Completed NCT01262573 Phase 4
23 A Comparison Between Continuous Infusion vs. Patient Controlled Intraabdominal Injection of Local Anesthetics for Treatment of Postoperative Pain After Abdominal Hysterectomy. A Randomized, Double-blind Study. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
24 Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis Recruiting NCT03500367 Phase 4 rapamycin
25 A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate Recruiting NCT03421639 Phase 4 Ulipristal acetate;Aromatase inhibitor plus GnRH analog
26 Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids Recruiting NCT03317795 Phase 4 Levonorgestrel IUS;Tranexamic Acid
27 A Randomized Control Trial of Combined Vaginal Misoprostol and Perivascular Vasopressin During Robotic Myomectomy Recruiting NCT03815344 Phase 4 Standard;Standard-vaginal misoprostol
28 Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial Recruiting NCT02209545 Phase 4 Misoprostol;Placebo
29 Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena, a Randomized Clinical Trial Recruiting NCT03186586 Phase 4 Ulipristal acetate;Placebo
30 Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population Active, not recruiting NCT02825719 Phase 4 Ulipristal acetate;Ferrous sulphate;Tranexamic Acid
31 Use of Oxytocin in MRI-HIFU Treatment Enrolling by invitation NCT03937401 Phase 4 Oxytocin
32 The Effect of Estrogen in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis Enrolling by invitation NCT03620929 Phase 4 Estradiol Valerate
33 Safety and Efficacy of Intravenous Oxytocin Versus Tranexamic Acid in Reducing Blood Loss During Abdominal Myomectomy; A Randomized Controlled Trial Not yet recruiting NCT03892668 Phase 4 Tranexamic Acid;oxytocin;placebo
34 Magnetic Resonance Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids in Women Desiring Future Pregnancies Terminated NCT00180739 Phase 4
35 Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies Terminated NCT03210324 Phase 4 Mifepristone tablets
36 A Prospective Randomized Blinded Placebo Controlled Comparison of Multimodal Pre-emptive Analgesia on Long Term Outcome Following Uterine Artery Embolization Terminated NCT01555073 Phase 4 pregabalin/celecoxib;pregabalin/placebo;celecoxib/placebo;Placebo group
37 Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized Terminated NCT01776203 Phase 4 Medroxyprogesterone 17-Acetate
38 Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis Withdrawn NCT03325868 Phase 4 Ulipristal Acetate
39 Multi-Center Clinical Trial of Uterine Artery Embolization Treatment of Uterine Leiomyoma Unknown status NCT00821275 Phase 2, Phase 3
40 A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids Unknown status NCT02189083 Phase 3 TSD
41 Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients Unknown status NCT03134157 Phase 3 oral drug and vaginal placebo;oral drug and oral placebo;Vaginal placebo+ oral placebo
42 Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses Unknown status NCT01833871 Phase 2, Phase 3
43 Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns Unknown status NCT01280045 Phase 3
44 A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy Unknown status NCT02011659 Phase 3 Ramosetron
45 Multi-institution, Randomized Trial for Efficacy and Safety of Single Incision Laparoscopic Surgery (SILS) Versus Conventional Laparoscopic Hysterectomy for the Treatment of Uterine Myoma or Adenomyosis Unknown status NCT01483417 Phase 3
46 Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions Unknown status NCT02866045 Phase 3
47 To Compare to Single-port Access Laparoscopic-assisted Vaginal Hysterectomy (LAVH) and Multiple Ports LAVH: A Randomized Controlled Trial Unknown status NCT01048931 Phase 3
48 Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome Unknown status NCT02491320 Phase 3 Letrozole
49 MR Guided Focused Ultrasound Surgery in the Treatment of Uterine Fibroids: Clinical Study to Validate the Changes to ExAblate 2000 Device Completed NCT00295217 Phase 3
50 A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas Completed NCT02147197 Phase 3 Ulipristal acetate (UPA);Placebo

Search NIH Clinical Center for Leiomyoma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Leuprolide
Leuprolide Acetate

Cochrane evidence based reviews: leiomyoma

Genetic Tests for Leiomyoma

Anatomical Context for Leiomyoma

MalaCards organs/tissues related to Leiomyoma:

41
Uterus, Smooth Muscle, Breast, Small Intestine, Lung, Prostate, Ovary

Publications for Leiomyoma

Articles related to Leiomyoma:

(show top 50) (show all 11423)
# Title Authors PMID Year
1
Progesterone is essential for maintenance and growth of uterine leiomyoma. 9 38
20375184 2010
2
Cell-type specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. 9 38
20414849 2010
3
Changes related to phosphatidylinositol 3-kinase/Akt signaling in leiomyomas: possible involvement of glycogen synthase kinase 3alpha and cyclin D2 in the pathophysiology. 9 38
19464003 2010
4
Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. 9 38
20414841 2010
5
Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. 9 38
19328471 2010
6
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells. 9 38
19906824 2010
7
Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. 9 38
20124487 2010
8
Mayer-Rokitansky-Kustner Hauser syndrome complicated by either uterine leiomyoma or ovarian tumor. 9 38
20178550 2010
9
Reactive oxygen species mediate mitogenic growth factor signaling pathways in human leiomyoma smooth muscle cells. 9 38
19741209 2010
10
Association of N-terminal pro B-type natriuretic peptide and sex hormone-binding globulin in non-obese peri- and postmenopausal women. 9 38
19945451 2010
11
A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. 9 38
19135657 2010
12
Transforming growth factor beta3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas. 9 38
19700613 2009
13
Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells. 9 38
19808856 2009
14
Atypical leiomyomas of the uterus with long-term follow-up after myomectomy with immunohistochemical analysis for p16INK4A, p53, Ki-67, estrogen receptors, and progesterone receptors. 9 38
19851199 2009
15
A leiomyoma presenting as an exophytic periurethral mass: a case report and review of the literature. 9 38
19573833 2009
16
High aromatase expression in uterine leiomyoma tissues of African-American women. 9 38
19240151 2009
17
Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN. 9 38
19176543 2009
18
Human uterine smooth muscle and leiomyoma cells differ in their rapid 17beta-estradiol signaling: implications for proliferation. 9 38
19179429 2009
19
Downregulation of SRF-FOS-JUNB pathway in fumarate hydratase deficiency and in uterine leiomyomas. 9 38
19151755 2009
20
A case of benign metastasizing leiomyoma treated by surgical castration followed by an aromatase inhibitor, anastrozole. 9 38
18523791 2009
21
Overexpression of HMGA2 in uterine leiomyomas points to its general role for the pathogenesis of the disease. 9 38
18980243 2009
22
Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients. 9 38
18249392 2009
23
Genistein suppresses spontaneous oviduct tumorigenesis in quail. 9 38
20155619 2009
24
Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk. 9 38
18691687 2008
25
Estrogen receptor alpha (ERalpha) phospho-serine-118 is highly expressed in human uterine leiomyomas compared to matched myometrium. 9 38
18853184 2008
26
Estrogen receptor alpha and beta in uterine fibroids: a basis for altered estrogen responsiveness. 9 38
18166184 2008
27
The expression of estrogen receptor isoforms alpha, beta and insulin-like growth factor-I in uterine leiomyoma. 9 38
19012097 2008
28
Treatment of symptomatic uterine leiomyoma with letrozole. 9 38
18854113 2008
29
[Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus]. 9 38
18565690 2008
30
Potential link between estrogen receptor-alpha gene hypomethylation and uterine fibroid formation. 9 38
18701604 2008
31
Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience. 9 38
18710984 2008
32
[Fibroblast growth factor gene expression in uterine leiomyomas]. 9 38
18819464 2008
33
Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. 9 38
18580309 2008
34
Effects of letrozole on proliferation and apoptosis in cultured leiomyoma cells treated with prostaglandin E(2). 9 38
18164802 2008
35
Differential metabolic consequences of fumarate hydratase and respiratory chain defects. 9 38
18313410 2008
36
CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. 9 38
18448745 2008
37
Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. 9 38
18403645 2008
38
Selective progesterone receptor modulator asoprisnil down-regulates collagen synthesis in cultured human uterine leiomyoma cells through up-regulating extracellular matrix metalloproteinase inducer. 9 38
18281245 2008
39
CCAAT/enhancer binding protein beta regulates aromatase expression via multiple and novel cis-regulatory sequences in uterine leiomyoma. 9 38
18182446 2008
40
Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells. 9 38
18216291 2008
41
[Expression of CD117, CD34, SMA, S-100 protein, Vim and desmin in patients with gastrointestinal stromal tumors]. 9 38
18359707 2008
42
Expression of sex hormone-binding globulin, oxytocin receptor, caveolin-1 and p21 in leiomyoma. 9 38
17952758 2008
43
Chemoprevention of fibroid tumors by [-]-epigallocatechin-3-gallate in quail. 9 38
19083394 2008
44
A limited immunocytochemical panel for the distinction of subepithelial gastrointestinal mesenchymal neoplasms sampled by endoscopic ultrasound-guided fine-needle aspiration. 9 38
18208801 2008
45
Expression of mRNA for chemokines and chemokine receptors in tissues of the myometrium and uterine leiomyoma. 9 38
19024011 2008
46
Association study between catechol-O-methyltransferase polymorphisms and uterine leiomyomas in a Japanese population. 9 38
18390078 2008
47
Comparative effects of SPRM asoprisnil (J867) on proliferation, apoptosis, and the expression of growth factors in cultured uterine leiomyoma cells and normal myometrial cells. 9 38
18089606 2007
48
Early growth response gene-1 plays a pivotal role in down-regulation of a cohort of genes in uterine leiomyoma. 9 38
17975260 2007
49
"Seedling" mesenchymal tumors (gastrointestinal stromal tumors and leiomyomas) are common incidental tumors of the esophagogastric junction. 9 38
18059218 2007
50
Frequency and characterization of HMGA2 and HMGA1 rearrangements in mesenchymal tumors of the lower genital tract. 9 38
17654722 2007

Variations for Leiomyoma

Expression for Leiomyoma

Search GEO for disease gene expression data for Leiomyoma.

Pathways for Leiomyoma

GO Terms for Leiomyoma

Cellular components related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 TGFB3 S100A1 IL17B GNRH1 DPT COL4A6
2 collagen-containing extracellular matrix GO:0062023 9.46 TGFB3 DPT COL4A6 COL4A5
3 collagen type IV trimer GO:0005587 8.62 COL4A6 COL4A5

Biological processes related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 TGFB3 MED12 HMGA2 ESR2 ESR1
2 cell-cell signaling GO:0007267 9.62 PGR IL17B GNRH1 ESR2
3 uterus development GO:0060065 9.46 ESR1 CYP19A1
4 androgen metabolic process GO:0008209 9.4 ESR1 CYP19A1
5 collagen-activated tyrosine kinase receptor signaling pathway GO:0038063 9.37 COL4A6 COL4A5
6 paracrine signaling GO:0038001 9.26 PGR CD34
7 transcription initiation from RNA polymerase II promoter GO:0006367 9.26 PGR MED12 ESR2 ESR1
8 embryonic neurocranium morphogenesis GO:0048702 9.16 TGFB3 MED12
9 intracellular steroid hormone receptor signaling pathway GO:0030518 9.13 ESR1
10 mammary gland development GO:0030879 8.8 TGFB3 PGR CYP19A1

Molecular functions related to Leiomyoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATPase binding GO:0051117 9.54 S100A1 PGR ESR1
2 steroid hormone receptor activity GO:0003707 9.5 PGR ESR2 ESR1
3 nuclear receptor activity GO:0004879 9.33 PGR ESR2 ESR1
4 estrogen receptor activity GO:0030284 9.26 ESR2 ESR1
5 estrogen response element binding GO:0034056 8.96 ESR2 ESR1
6 steroid binding GO:0005496 8.8 PGR ESR2 ESR1

Sources for Leiomyoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....